Skip to main content
. 2015 Aug 22;6(29):26909–26921. doi: 10.18632/oncotarget.4817

Figure 1. A genome-wide dropout screen uncovers putative shRNAs that potentiate fluvastatin-induced cell death.

Figure 1

A. A simplified schematic of the mevalonate (MVA) pathway. Double arrows represent multiple steps in the pathway. B. In the pooled, genome-wide dropout screen A549 cells that had been stably transduced with the library of 80K shRNAs were treated with sublethal doses of fluvastatin (4–5 μM) every 3 days, over 12 days. C. Viability as assessed by trypan blue exclusion, relative to control of the fluvastatin-treated replicates. D. Significant hits, HMGCS1, GGPS1 and SREBP2, chosen for follow-up are indicated on the scatterplot (diamonds).